Clinical and immunological changes in patients with active moderate-to-severe Graves ̕ orbitopathy treated with very low-dose rituximab.

CONCLUSIONS: A single very low-dose of rituximab appears to be very well tolerated and effective enough to reduce clinical activity in active moderate-to-severe GO patients without impending DON. PMID: 28660988 [PubMed - as supplied by publisher]
Source: Endokrynologia Polska - Category: Endocrinology Authors: Tags: Endokrynol Pol Source Type: research